<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) is an aggressive <z:hpo ids='HP_0002664'>neoplasm</z:hpo> with a short survival </plain></SENT>
<SENT sid="1" pm="."><plain>Cases with leukaemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> without <z:mp ids='MP_0000702'>adenopathies</z:mp> (non-nodal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) may have a more indolent course </plain></SENT>
<SENT sid="2" pm="."><plain>To gain insights into the biological features underlying this presentation, we investigated the gene expression profile (GEP) and the IGHV mutational status in a cohort of leukaemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> cases </plain></SENT>
<SENT sid="3" pm="."><plain>Comparison of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> with other <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (i.e. splenic marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>) revealed a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> signature enriched for the following gene categories: mitochondrion, oxidoreductase activity, response to stress, to DNA damage and TP53-pathway </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, GEP analysis revealed that non-nodal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> cases were characterized by the down-modulation of the following gene categories: cell projection, actin cytoskeleton organization, cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> (ITGAE, CELSR1, PCDH9) and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> invasion/progression (<z:chebi fb="0" ids="26340">PGF</z:chebi>, ST14, ETS1, OCIAD1, EZR) </plain></SENT>
<SENT sid="5" pm="."><plain>Many down-modulated genes were related to the TP53-pathway and to DNA damage response </plain></SENT>
<SENT sid="6" pm="."><plain>IGHV status proved unmutated in <z:hpo ids='HP_0000001'>all</z:hpo> nodal and mutated in <z:hpo ids='HP_0000001'>all</z:hpo> non-nodal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Non-nodal leukaemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCLs</z:e> display a peculiar clinical presentation, with distinctive biological features, such as mutated IGHV and a transcriptional profile lacking <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> invasion properties, that might contribute to the absence of nodal involvement and to the less aggressive clinical course </plain></SENT>
</text></document>